Skip to main content

Table 1 Comparison of systemic therapy for advanced (unresectable stage III or stage IV) melanoma

From: Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Treatment

RR (%)

PFS (med), months

OS (med/2-years)

Single-agent BRAFi

50

6–8

18.7 months/~ 40%

Combo BRAFi and MEKi

65–70

9–12

15 months/~ 50%

Ipilimumab

10

2–3

12 months/~ 30%

(20% 5 year survival)

Anti-PD-1 mAb (nivolumab or pembrolizumab)

25–45

~ 6

18–24 months/~ 50%

Combo ipilimumab and nivolumab

~ 60

11–12

Unk./~ 64%